Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Last updated: July 28, 2025
Sponsor: October 6 University
Overall Status: Active - Recruiting

Phase

2/3

Condition

Ovarian Cysts

Dysfunctional Uterine Bleeding

Treatment

Metformin Hydrochloride tablet

Vildagliptin 50 MG

Clinical Study ID

NCT06142656
PRC-Ph-2307004
  • Ages 18-50
  • Female

Study Summary

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM

Eligibility Criteria

Inclusion

Inclusion Criteria:

-Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.

Exclusion

Exclusion Criteria:

  • Patients with history of diabetes mellitus (Type 1 or 2).

  • Patients with liver or renal dysfunction; inflammatory diseases; autoimmune disease;cancer, acute cardiovascular event within last three months

  • Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4)inhibitors

  • Eating disorders (anorexia, bulimia) or gastrointestinal disorders

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Metformin Hydrochloride tablet
Phase: 2/3
Study Start date:
November 25, 2023
Estimated Completion Date:
February 01, 2026

Connect with a study center

  • October 6 university hospital

    Giza, 12585
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.